| Code | Display | Comments |
|---|
 93028-9 | Have you spent more than 2 nights in a row in a jail, prison, detention center, or juvenile correctional facility in past 1 year [PRAPARE] | | |
| 93025-5 | Protocol for Responding to and Assessing Patients' Assets, Risks, and Experiences [PRAPARE] | | |
| 69861-3 | Because of a physical, mental, or emotional condition, do you have difficulty doing errands alone such as visiting a physician's office or shopping | | |
| 93027-1 | Are you a refugee | | |
| 81375-8 | Self assessment of health status [Reported] | | |
| 93034-7 | Discharged from the U.S. Armed Forces | | |
| 68516-4 | On those days that you engage in moderate to strenuous exercise, how many minutes, on average, do you exercise | | |
| 96782-8 | Wants help with school or training | | |
| 93029-7 | How often do you see or talk to people that you care about and feel close to [PRAPARE] | | |
| 68517-2 | How many times in the past year have you have X or more drinks in a day | | |
| 96842-0 | How often have you used any tobacco product in past 12 months | | |
| 88123-5 | Within the past 12 months the food we bought just didn't last and we didn't have money to get more [U.S. FSS] | | |
| 76501-6 | Within the last year, have you been afraid of your partner or ex-partner | | |
| 95618-5 | Physically hurt you [HITS] | | |
| 93038-8 | Stress level | | |
| 69858-9 | Because of a physical, mental, or emotional condition, do you have serious difficulty concentrating, remembering, or making decisions | | |
| 93159-2 | How often do you feel lonely or isolated from those around you [CMS Assessment] | | |
| 96780-2 | Wants help finding or keeping work or a job | | |
| 44250-9 | Little interest or pleasure in doing things in last 2 weeks | | |
| 68524-8 | How many times in the past year have you used an illegal drug or used a prescription medication for non-medical reasons | | |
| 88121-9 | Hunger Vital Sign [HVS] | | |
| 93026-3 | Do you feel physically and emotionally safe where you currently live [PRAPARE] | | |
| 82589-3 | Highest level of education | | |
| 89555-7 | How many days per week did you engage in moderate to strenuous physical activity in the last 30 days | | |
| 96781-0 | Able to get help with daily activities when needed | | |
| 95530-2 | Prescription drug use for non-medical reasons in the past year | | |
| 56799-0 | Address | | |
| 63586-2 | What was your best estimate of the total income of all family members from all sources, before taxes, in last year [PhenX] | | |
| 96779-4 | Has the electric, gas, oil, or water company threatened to shut off services in your home in past 12 months | | |
| 93677-3 | Do you need help with legal issues [WellRx] | | |
| 63512-8 | How many people are living or staying at this address [#] | | |
| 76437-3 | Primary insurance | | |
| 88124-3 | Food insecurity risk [HVS] | | |
| 32624-9 | Race | | |
| 97023-6 | Accountable health communities (AHC) health-related social needs (HRSN) supplemental questions | | |
| 93035-4 | Has season or migrant farm work been your or your family's main source of income at any point in past 2 years [PRAPARE] | | |
| 54899-0 | Preferred language | | |
| 93033-9 | Are you worried about losing your housing [PRAPARE] | | |
| 93031-3 | Have you or any family members you live with been unable to get any of the following when it was really needed in past 1 year [PRAPARE] | | |
| 56051-6 | Hispanic or Latino | | |
| 88122-7 | Within the past 12 months we worried whether our food would run out before we got money to buy more [U.S. FSS] | | |
| 93030-5 | Has lack of transportation kept you from medical appointments, meetings, work, or from getting things needed for daily living | | |
| 97027-7 | Speaks a language other than English at home | | |
| 71802-3 | Housing status | | |
| 44255-8 | Feeling down, depressed, or hopeless in last 2 weeks | | |
| 67875-5 | Employment status - current | | |
| 76513-1 | How hard is it for you to pay for the very basics like food, housing, medical care, and heating | | |
| 1-8 | | Acyclovir [Susceptibility] | |
| 10-9 | | Amdinocillin [Susceptibility] by Serum bactericidal titer | |
| 100-8 | | Cefoperazone [Susceptibility] by Minimum inhibitory concentration (MIC) | |
| 1000-9 | | DBG Ab [Presence] in Serum or Plasma from Blood product unit | |
| 10000-8 | | R wave duration in lead AVR | |
| 100002-5 | | Specimen care is maintained | |
| 100003-3 | | Team communication is maintained throughout care | |
| 100004-1 | | Demonstrates knowledge of the expected psychosocial responses to the procedure | |
| 100005-8 | | Demonstrates knowledge of nutritional management related to the procedure | |
| 100006-6 | | Demonstrates knowledge of medication management | |
| 100007-4 | | Demonstrates knowledge of pain management | |
| 100008-2 | | Demonstrates knowledge of wound management | |
| 100009-0 | | Demonstrates knowledge of the procedure and expected results | |
| 10001-6 | | R wave duration in lead I | |
| 100010-8 | | No injury related to procedure equipment, medical supplies, or instrumentation | |
| 100011-6 | | No injury related to an electrical source | |
| 100012-4 | | Participates in decisions affecting the patient's plan of care | |
| 100013-2 | | Participates in the discharge process | |
| 100014-0 | | Psychosocial health is maintained at or improved from baseline | |
| 100015-7 | | No injury related to positioning due to care or procedure | |
| 100016-5 | | No injury related to a laser source | |
| 100017-3 | | Perioperative nursing data set outcomes panel [PNDS] | |
| 100018-1 | | Hospice care Note | |
| 100019-9 | | ALK gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | |
| 10002-4 | | R wave duration in lead II | |
| 100020-7 | | GNA11 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | |
| 100021-5 | | GNAQ gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | |
| 100022-3 | | IDH1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | |
| 100023-1 | | IDH2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | |
| 100024-9 | | SETBP1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | |
| 100025-6 | | SRSF2 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | |
| 100026-4 | | MET gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | |
| 100027-2 | | SMAD4 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | |
| 100028-0 | | FBXW7 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal | |
| 100029-8 | | Cancer related multigene analysis in Plasma cell-free DNA by Molecular genetics method | |
| 10003-2 | | R wave duration in lead III | |
| 100030-6 | | Axis I: Temporal aspects score [Mainz Pain Staging System] | |
| 100031-4 | | Axis II: Spatial aspects score [Mainz Pain Staging System] | |
| 100032-2 | | Axis III: Drug taking behavior score [Mainz Pain Staging System] | |
| 100033-0 | | Axis IV: Utilization of the health care system score [Mainz Pain Staging System] | |
| 100034-8 | | Provider of automated external defibrillator use | |
| 100035-5 | | Exam finding location of Chest | |
| 100036-3 | | Exam finding location of Lung | |
| 100037-1 | | Patient contact disposition EMS unit | |
| 100038-9 | | Patient evaluation disposition EMS unit | |
| 100039-7 | | Crew disposition for patient care EMS unit | |
| 10004-0 | | R wave duration in lead V1 | |
| 100040-5 | | Patient transport disposition EMS unit | |
| 100041-3 | | Aminoglycoside [Susceptibility] | |
| 100042-1 | | Atovaquone [Susceptibility] | |
| 100043-9 | | Azithromycin+Ethambutol [Susceptibility] | |
| 100044-7 | | Cefcapene [Susceptibility] | |
| 100045-4 | | Cefozopran [Susceptibility] | |
| 100046-2 | | Cefquinome [Susceptibility] | |
| 100047-0 | | Cefteram [Susceptibility] | |
| 100048-8 | | Clarithromycin+Ethambutol [Susceptibility] | |
| 100049-6 | | Eravacycline [Susceptibility] | |
| 10005-7 | | R wave duration in lead V2 | |
| 100050-4 | | Erythromycin+Ethambutol [Susceptibility] | |
| 100051-2 | | Ethambutol+rifAMPin [Susceptibility] | |
| 100052-0 | | Flomoxef [Susceptibility] | |
| 100053-8 | | Fluoroquinolone [Susceptibility] | |
| 100054-6 | | Gamithromycin [Susceptibility] | |
| 100055-3 | | Optochin [Susceptibility] | |
| 100056-1 | | Panipenem [Susceptibility] | |
| 100057-9 | | Prothionamide [Susceptibility] | |
| 100058-7 | | Prulifloxacin [Susceptibility] | |
| 100059-5 | | Rifapentine [Susceptibility] | |
| 10006-5 | | R wave duration in lead V3 | |
| 100060-3 | | Tildipirosin [Susceptibility] | |
| 100061-1 | | Tosufloxacin [Susceptibility] | |
| 100062-9 | | Standard Dermatology Outcome Measures panel | |
| 100063-7 | | Primary skin concern | |
| 100064-5 | | Itch severity Reporting Period - Reported | |
| 100065-2 | | Satisfied with treatment | |
| 100066-0 | | Specular microscopy panel | |
| 100067-8 | | Eye Image magnification | |
| 100068-6 | | Right eye Fixation point [Angle] | |
| 100069-4 | | Left eye Fixation point [Angle] | |
| 10007-3 | | R wave duration in lead V4 | |
| 100070-2 | | Right cornea Cell density | |
| 100071-0 | | Left cornea Cell density | |
| 100072-8 | | Right cornea Coefficient of variation | |
| 100073-6 | | Left cornea Coefficient of variation | |
| 100074-4 | | Right cornea Hexagonality | |
| 100075-1 | | Left cornea Hexagonality | |
| 100076-9 | | Right cornea Endothelial cells counted | |
| 100077-7 | | Left cornea Endothelial cells counted | |
| 100078-5 | | Right cornea Endothelial cell area.min | |
| 100079-3 | | Left cornea Endothelial cell area.min | |
| 10008-1 | | R wave duration in lead V5 | |
| 100080-1 | | Right cornea Endothelial cell area.max | |
| 100081-9 | | Left cornea Endothelial cell area.max | |
| 100082-7 | | Right cornea Endothelial cell area.mean | |
| 100083-5 | | Left cornea Endothelial cell area.mean | |
| 100084-3 | | Right cornea Cell area.standard deviation | |
| 100085-0 | | Left cornea Cell area.standard deviation | |
| 100086-8 | | Right cornea Type of Analysis method by Specular microscopy | |
| 100087-6 | | Toxocara canis 24-35kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100088-4 | | Taenia solium larva Ab bands panel - Serum by Immunoblot | |
| 100089-2 | | Taenia solium larva 6-8kD Ab [Presence] in Serum by Immunoblot | |
| 10009-9 | | R wave duration in lead V6 | |
| 100090-0 | | Taenia solium larva 45kD Ab [Presence] in Serum by Immunoblot | |
| 100091-8 | | Trypanosoma cruzi Ab [Units/volume] in Serum by Immunoassay | |
| 100092-6 | | Trypanosoma cruzi Ab bands panel - Serum by Immunoblot | |
| 100093-4 | | Trypanosoma cruzi 15-16kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100094-2 | | Trypanosoma cruzi 21-22kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100095-9 | | Trypanosoma cruzi 27-28kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100096-7 | | Trypanosoma cruzi 42kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100097-5 | | Trypanosoma cruzi 45-47kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100098-3 | | Trypanosoma cruzi 120-200kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100099-1 | | Trypanosoma cruzi 160kD IgG Ab [Presence] in Serum by Immunoblot | |
| 1001-7 | | DBG Ab [Presence] in Serum or Plasma from Donor | |
| 10010-7 | | R' wave amplitude in lead AVF | |
| 100100-7 | | Fasciola sp IgG Ab [Presence] in Serum by Immunoassay | |
| 100101-5 | | Fasciola sp 8-9kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100102-3 | | Fasciola sp 27-28kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100103-1 | | Fasciola sp 60kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100104-9 | | Fasciola sp 42kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100105-6 | | Filaria IgG and IgM panel - Serum | |
| 100106-4 | | Filaria IgG Ab [Presence] in Serum by Immunoassay | |
| 100107-2 | | Leishmania sp IgG Ab [Presence] in Serum by Immunoassay | |
| 100108-0 | | Leishmania sp IgG Ab [Units/volume] in Serum by Immunoassay | |
| 100109-8 | | Leishmania sp Ab bands panel - Serum by Immunoblot | |
| 10011-5 | | R' wave amplitude in lead AVL | |
| 100110-6 | | Leishmania sp 14kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100111-4 | | Leishmania sp 16kD IgG Ab [Presence] in Serum by Immunoblot | |
| 100112-2 | | Fasciola sp Ab bands panel - Serum by Immunoblot | |
| 100113-0 | | Helicobacter pylori Ab panel - Serum | |
| 100114-8 | | Toxoplasma gondii 30kD Ab [Presence] in Serum by Immunoblot | |
| 100115-5 | | Toxoplasma gondii 31kD Ab [Presence] in Serum by Immunoblot | |
| 100116-3 | | Toxoplasma gondii 33kD Ab [Presence] in Serum by Immunoblot | |
| 100117-1 | | Toxoplasma gondii 40kD Ab [Presence] in Serum by Immunoblot | |
| 100118-9 | | Toxoplasma gondii 41kD Ab [Presence] in Serum by Immunoblot | |
| 100119-7 | | Toxoplasma gondii 45kD Ab [Presence] in Serum by Immunoblot | |
| 10012-3 | | R' wave amplitude in lead AVR | |
| 100120-5 | | Chlamydia trachomatis Ab panel - Serum | |
| 100121-3 | | Chlamydia trachomatis IgA Ab [Presence] in Serum by Immunoassay | |
| 100122-1 | | Chlamydophila pneumoniae Ab panel - Serum | |
| 100123-9 | | Chlamydophila pneumoniae IgA Ab [Presence] in Serum by Immunoassay | |
| 100124-7 | | Chlamydophila pneumoniae IgA Ab [Units/volume] in Serum by Immunoassay | |
| 100125-4 | | Chlamydophila psittaci Ab panel - Serum | |
| 100126-2 | | Bordetella pertussis Ab.IgG panel - Serum | |
| 100127-0 | | Campylobacter sp Ab panel - Serum | |
| 100128-8 | | Cryptococcus sp Ag panel - Serum | |
| 100129-6 | | Schistosoma sp Ab [Titer] in Serum by Hemagglutination | |
| 10013-1 | | R' wave amplitude in lead I | |
| 100130-4 | | Schistosoma mansoni Ab [Presence] in Serum by Immunoblot | |
| 100131-2 | | Schistosoma sp 8kD Ab [Presence] in Serum by Immunoblot | |
| 100132-0 | | Schistosoma sp 9kD Ab [Presence] in Serum by Immunoblot | |
| 100133-8 | | Schistosoma sp 10kD Ab [Presence] in Serum by Immunoblot | |
| 100134-6 | | Schistosoma sp 11kD Ab [Presence] in Serum by Immunoblot | |
| 100135-3 | | Schistosoma sp 12-13kD Ab [Presence] in Serum by Immunoblot | |
| 100136-1 | | Schistosoma sp 14-15kD Ab [Presence] in Serum by Immunoblot | |
| 100137-9 | | Schistosoma sp 15-16kD Ab [Presence] in Serum by Immunoblot | |
| 100138-7 | | Schistosoma sp 18-19kD Ab [Presence] in Serum by Immunoblot | |
| 100139-5 | | Schistosoma sp 22-24kD Ab [Presence] in Serum by Immunoblot | |
| 10014-9 | | R' wave amplitude in lead II | |
| 100140-3 | | Schistosoma sp 30-34kD Ab [Presence] in Serum by Immunoblot | |
| 100141-1 | | Schistosoma sp 65kD Ab [Presence] in Serum by Immunoblot | |
| 100142-9 | | Schistosoma sp 70kD Ab [Presence] in Serum by Immunoblot | |
| 100143-7 | | Schistosoma sp 80kD Ab [Presence] in Serum by Immunoblot | |
| 100144-5 | | Schistosoma sp 95kD Ab [Presence] in Serum by Immunoblot | |
| 100145-2 | | Schistosoma sp 110kD Ab [Presence] in Serum by Immunoblot | |
| 100146-0 | | Schistosoma sp 120kD Ab [Presence] in Serum by Immunoblot | |
| 100147-8 | | Toxoplasma gondii Ab bands panel - Serum by Immunoblot | |
| 100148-6 | | Schistosoma sp Ab bands panel - Serum by Immunoblot | |
| 100149-4 | | 6-oxo-piperidine-2-carboxylate and 6(R+S)-oxo-propylpiperidine-2-carboxylate panel - Urine and Serum or Plasma | |
| 10015-6 | | R' wave amplitude in lead III | |
| 100150-2 | | 6(R+S)-oxo-propylpiperidine-2-carboxylate [Moles/volume] in Plasma | |
| 100151-0 | | 6-oxo-piperidine-2-carboxylate [Moles/volume] in Plasma | |
| 100152-8 | | 6-oxo-piperidine-2-carboxylate/Creatinine [Molar ratio] in Urine | |
| 100153-6 | | 6(R+S)-oxo-propylpiperidine-2-carboxylate/Creatinine [Molar ratio] in Urine | |
| 100154-4 | | Specimen collection supervision level | |
| 100155-1 | | Left cornea Type of Analysis method by Specular microscopy | |
| 100156-9 | | SARS-CoV-2 (COVID-19) variant [Type] in Specimen by NAA with probe detection | |
| 100157-7 | | SARS-CoV-2 (COVID-19) lineage [Type] in Specimen by Sequencing | |
| 100158-5 | | Microalbumin [Mass/volume] in Urine collected for unspecified duration | |
| 100159-3 | | Knee Society Score pre-op panel [Knee Society Score] | |
| 10016-4 | | R' wave amplitude in lead V1 | |
| 100160-1 | | Knee replacement | |
| 100161-9 | | Charnley Functional Classification | |
| 100162-7 | | Knee alignment W standing X-ray measured | |
| 100163-5 | | Knee medial AndOr lateral instability W full extension | |
| 100164-3 | | Knee AP instability W 90 degree flexion | |
| 100165-0 | | Knee range of motion | |
| 100166-8 | | Flexion contracture range of Knee | |
| 100167-6 | | Extensor lag range of Knee | |
| 100168-4 | | Knee pain severity with level walking | |
| 100169-2 | | Knee pain severity with stairs or inclines | |
| 10017-2 | | R' wave amplitude in lead V2 | |
| 100170-0 | | Knee feels normal | |
| 100171-8 | | Satisfaction with level of knee pain while sitting | |
| 100172-6 | | Satisfaction with level of knee pain while lying in bed | |
| 100173-4 | | Satisfaction with knee function while getting out of bed | |
| 100174-2 | | Satisfaction with knee function while performing light household duties | |
| 100175-9 | | Satisfaction with knee function while performing recreational activities | |
| 100176-7 | | Expect surgery to relieve pain | |
| 100177-5 | | Expect surgery will improve ability to perform activities of daily living | |
| 100178-3 | | Expect surgery will improve ability to perform leisure, recreational, or sports activities | |
| 100179-1 | | Walk without assistive mobility devices | |
| 10018-0 | | R' wave amplitude in lead V3 | |
| 100180-9 | | Assistive mobility devices used | |
| 100181-7 | | Assistive mobility devices used due to health condition | |
| 100182-5 | | Duration of standing before sitting due to knee discomfort | |
| 100183-3 | | Duration of walking before stopping due to knee discomfort | |
| 100184-1 | | How bothersome is knee when walking on an uneven surface | |
| 100185-8 | | How bothersome is knee when turning or pivoting leg | |
| 100186-6 | | How bothersome is knee when climbing up or down a flight of stairs | |
| 100187-4 | | How bothersome is knee when getting up from a low seat without armrests | |
| 100188-2 | | How bothersome is knee when getting into or out of a car | |
| 100189-0 | | How bothersome is knee when moving laterally | |
| 10019-8 | | R' wave amplitude in lead V4 | |
| 100190-8 | | How bothersome is knee when climbing a ladder or step stool | |
| 100191-6 | | How bothersome is knee when carrying a bag for one block | |
| 100192-4 | | How bothersome is knee when squatting | |
| 100193-2 | | How bothersome is knee when kneeling | |
| 100194-0 | | How bothersome is knee when running | |
| 100195-7 | | Pain severity--during activity | |
| 100196-5 | | Pre-op total score [Knee Society Score] | |
| 100197-3 | | Exercise activity and pain severity panel | |
| 100198-1 | | Pre-op objective knee indicators score [Knee Society Score] | |
| 100199-9 | | Pre-op symptoms score [Knee Society Score] | |
| 1002-5 | | DBG Ab [Presence] in Serum or Plasma | |
| 10020-6 | | R' wave amplitude in lead V5 | |
| 100200-5 | | Pre-op patient expectations score [Knee Society Score] | |
| 100201-3 | | Pre-op functional activities score [Knee Society Score] | |
| 100202-1 | | Pre-op discretionary knee activities score [Knee Society Score] | |
| 100203-9 | | Knee Society Score post-op panel [Knee Society Score] | |
| 100204-7 | | Accuracy of pre-surgery expectations of pain relief | |
| 100205-4 | | Accuracy of pre-surgery expectations to perform activities of daily living | |
| 100206-2 | | Accuracy of pre-surgery expectations to perform leisure, recreational, or sports activities | |
| 100207-0 | | Post-op total score [Knee Society Score] | |
| 100208-8 | | Post-op objective knee indicators score [Knee Society Score] | |
| 100209-6 | | Post-op symptoms score [Knee Society Score] | |
| 10021-4 | | R' wave amplitude in lead V6 | |
| 100210-4 | | Post-op patient expectations score [Knee Society Score] | |
| 100211-2 | | Post-op functional activities score [Knee Society Score] | |
| 100212-0 | | Post-op discretionary knee activities score [Knee Society Score] | |
| 100213-8 | | Prostate cancer multigene analysis in Blood or Tissue by Molecular genetics method | |
| 100214-6 | | Dental model prior authorization Document | |
| 100215-3 | | Episode of care medical records Document Transplant surgery | |
| 100216-1 | | Surgical synoptic report | |
| 100217-9 | | Surgical oncology synoptic report | |
| 100218-7 | | Surgical oncology of colon synoptic report | |
| 100219-5 | | Surgical oncology of melanoma synoptic report | |
| 10022-2 | | R' wave duration in lead AVF | |
| 100220-3 | | Surgical oncology of breast synoptic report | |
| 100221-1 | | Surgical oncology of thyroid synoptic report | |
| 100222-9 | | Surgical oncology of pancreas synoptic report | |
| 100223-7 | | Physical findings of Retina Narrative | |
| 100224-5 | | Cardiac left ventricular segmental wall motion by echo panel | |
| 100225-2 | | Bone density quantitative ultrasound study | |
| 100226-0 | | Small bowel capsule endoscopy study Document | |
| 100227-8 | | Colon capsule endoscopy study Document | |
| 100228-6 | | Upper gastrointestinal capsule endoscopy study Document | |
| 100229-4 | | Endoscopic ultrasound study Document | |
| 10023-0 | | R' wave duration in lead AVL | |
| 100230-2 | | Routine prenatal assessment panel | |
| 100231-0 | | Endobronchial ultrasound study | |
| 100232-8 | | Impacts of Events Scale-Revised panel | |
| 100233-6 | | Reminders brought back feelings about adverse event | |
| 100234-4 | | Trouble staying asleep | |
| 100235-1 | | Other things triggered persistent thoughts about adverse event | |
| 100236-9 | | Felt irritable AndOr angry | |
| 100237-7 | | Avoided getting upset when unintentionally thought about adverse event | |
| 100238-5 | | Thought about adverse event unintentionally | |
| 100239-3 | | Felt as if adverse event did not happen | |
| 10024-8 | | R' wave duration in lead AVR | |
| 100240-1 | | Avoided reminders of adverse event | |
| 100241-9 | | Experienced mental images of adverse event | |
| 100242-7 | | Easily startled | |
| 100243-5 | | Tried to not think of adverse event | |
| 100244-3 | | Aware of feelings about adverse event, but did not address them | |
| 100245-0 | | Feelings about adverse event were numb | |
| 100246-8 | | Acted or felt the same as during adverse event | |
| 100247-6 | | Trouble falling asleep | |
| 100248-4 | | Waves of strong feelings about adverse event | |
| 100249-2 | | Tried to remove adverse event from memory | |
| 10025-5 | | R' wave duration in lead I | |
| 100250-0 | | Trouble concentrating | |
| 100251-8 | | Reminders of adverse event caused physical reactions | |
| 100252-6 | | Had dreams about adverse event | |
| 100253-4 | | Felt watchful and on-guard | |
| 100254-2 | | Tried not to talk about adverse event | |
| 100255-9 | | Total score [Impact of Event Scale-Revised] | |
| 100256-7 | | Fallen in last 6 months | |
| 100257-5 | | Feel unsteady when standing or walking | |
| 100258-3 | | History of fall related injury | |
| 100259-1 | | Aware of tactile sensations | |
| 10026-3 | | R' wave duration in lead II | |
| 100260-9 | | Easy to describe thoughts AndOr feelings | |
| 100261-7 | | Critical of own thoughts AndOr feelings | |
| 100262-5 | | Able to notice distressing thoughts AndOr feelings without having to react | |
| 100263-3 | | Easily distracted | |
| 100264-1 | | Able to notice thoughts AndOr feelings without being overwhelmed | |
| 100265-8 | | Aware of dietary intake impact on self | |
| 100266-6 | | Difficult to describe thoughts AndOr feelings | |
| 100267-4 | | Aware of auditory stimuli | |
| 100268-2 | | Able to avoid immediate reaction in difficult situations | |
| 100269-0 | | Do things without paying attention | |
| 10027-1 | | R' wave duration in lead III | |
| 100270-8 | | Recover quickly from distressing thoughts AndOr images | |
| 100271-6 | | Aware of olfactory stimuli | |
| 100272-4 | | Aware of visual stimuli | |
| 100273-2 | | Aware of emotions affect on thoughts AndOr behavior | |
| 100274-0 | | Observing score [FFMQ] | |
| 100275-7 | | Describing score [FFMQ] | |
| 100276-5 | | Acting with awareness score [FFMQ] | |
| 100277-3 | | Nonjudging score [FFMQ] | |
| 100278-1 | | Nonreactivity score [FFMQ] | |
| 100279-9 | | Total score [FFMQ] | |
| 10028-9 | | R' wave duration in lead V1 | |
| 100280-7 | | Five Facet Mindfulness Questionnaire panel [FFMQ] | |
| 100281-5 | | D Ab [Units/volume] in Serum or Plasma | |
| 100282-3 | | Vaccine exemption certificate | |
| 100283-1 | | Harris Hip Score panel [Harris Hip Score] | |
| 100284-9 | | Walking - functional ability | |
| 100285-6 | | Comfortable seated position | |
| 100286-4 | | Able to board public transportation | |
| 100287-2 | | Put on shoes and socks | |
| 100288-0 | | Absence of deformity score [Harris Hip Score] | |
| 100289-8 | | Absence of hip deformity measurements | |
| 10029-7 | | R' wave duration in lead V2 | |
| 100290-6 | | Range of motion score [Harris Hip Score] | |
| 100291-4 | | Total score [Harris Hip Score] | |
| 100292-2 | | Pre-op patient satisfaction score [Knee Society Score] | |
| 100293-0 | | Hip Flexion range of motion | |
| 100294-8 | | Hip Abduction range of motion | |
| 100295-5 | | Hip Adduction range of motion | |
| 100296-3 | | Hip External rotation range of motion | |
| 100297-1 | | Hip Internal rotation range of motion | |
| 100298-9 | | Repetition count | |
| 100299-7 | | Post-op patient satisfaction score [Knee Society Score] | |
| 1003-3 | | Indirect antiglobulin test.complement specific reagent [Presence] in Serum or Plasma | |
| 10030-5 | | R' wave duration in lead V3 | |
| 100300-3 | | End time Unspecified body region | |
| 100301-1 | | Start time Unspecified body region | |
| 100302-9 | | Time period start and end panel Unspecified body region | |
| 100303-7 | | Condition certainty of presence | |
| 100304-5 | | Flights climbed [#] Reporting Period | |
| 100305-2 | | IDH1 gene exon 4 targeted mutation analysis [Presence] in Blood or Marrow by Molecular genetics method | |
| 100306-0 | | IDH2 gene exon 4 targeted mutation analysis [Presence] in Blood or Marrow by Molecular genetics method | |
| 100307-8 | | Behavioral screening elder mistreatment | |
| 100308-6 | | Need help getting to essential places | |
| 100309-4 | | Activity support person | |
| 10031-3 | | R' wave duration in lead V4 | |
| 100310-2 | | Reliability of support person | |
| 100311-0 | | Need help to make sure there is enough food, medicines or any other things needed in house | |
| 100312-8 | | Person or persons that makes sure there is enough food, medicines or any other things needed in house | |
| 100313-6 | | Need help with household things such as cook meals, help feed, or provide correct medicines each day | |
| 100314-4 | | Need help with house cleaning or yard work | |
| 100315-1 | | Need help getting out of bed, showered, or dressed | |
| 100316-9 | | Need help to make sure bills get paid | |
| 100317-7 | | Relationship of usual support person for daily activities | |
| 100318-5 | | Have help with finances AndOr financial decisions | |
| 100319-3 | | Relationship of financial support person | |
| 10032-1 | | R' wave duration in lead V5 | |
| 100320-1 | | Financial support person usually asks for permission before making decisions | |
| 100321-9 | | Financial support person usually makes good decisions about finances | |
| 100322-7 | | Have access to paperwork for financial decisions made | |
| 100323-5 | | Financial support person forged signature | |
| 100324-3 | | Coercion of financial support person for signing a document in order to get money or possessions | |
| 100325-0 | | Experienced theft by support person | |
| 100326-8 | | Money spent or property sold without permission | |
| 100327-6 | | Stranger forged signature for financial gain | |
| 100328-4 | | Stranger forced document signature for financial gain | |
| 100329-2 | | Feared for safety due to verbal attack | |
| 10033-9 | | R' wave duration in lead V6 | |
| 100330-0 | | Felt humiliated due to ridicule | |
| 100331-8 | | Coerced to do something | |
| 100332-6 | | Ignored by close friend or relative for extended period | |
| 100333-4 | | Physically hit or threatened | |
| 100334-2 | | Been physically hurt with some degree of injury | |
| 100335-9 | | Coerced sexual activity | |
| 100336-7 | | Coerced touching of private body parts of self or others | |
| 100337-5 | | Coerced to undress or expose private body area | |
| 100338-3 | | Photographed in any degree of nudity without consent | |
| 100339-1 | | Experienced attempted physical restraint | |
| 10034-7 | | S wave amplitude in lead AVF | |
| 100340-9 | | Range of motion panel Hip | |
| 100341-7 | | Rubella virus IgG Ab index [Units/volume] in Serum and CSF | |
| 100342-5 | | Volatile Organic Compounds associated with SARS-CoV-2 infection [Presence] in Exhaled gas by Gas chromatography-mass spectrometry | |
| 100343-3 | | Influenza virus B RNA [Presence] in Saliva (oral fluid) by NAA with probe detection | |
| 100344-1 | | Influenza virus A RNA [Presence] in Saliva (oral fluid) by NAA with probe detection | |
| 100345-8 | | Influenza virus A and B and SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection | |
| 100346-6 | | Clotting time.extrinsic coagulation system activated.platelets inhibited of Blood by Rotational TEG | |
| 100347-4 | | Clot formation.extrinsic coagulation system activated.platelets inhibited [Time] in Blood by Rotational TEG | |
| 100348-2 | | Model for end-stage liver disease sodium score | |
| 100349-0 | | US.doppler Penis vessels W vasodilator IV | |
| 10035-4 | | S wave amplitude in lead AVL | |
| 100350-8 | | Sesamum indicum 1 IgE Ab [Units/volume] in Serum | |
| 100351-6 | | Pioglitazone [Presence] in Serum or Plasma | |
| 100352-4 | | Rosiglitazone [Presence] in Serum or Plasma | |
| 100353-2 | | Norwalk Community Health Center Screening Tool [NCHC] | |
| 100354-0 | | Frequency of participating in multi-modal communication without assistance | |
| 100355-7 | | Frequency of participating in spoken language expression communication without assistance | |
| 100356-5 | | Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis DNA [Identifier] in Specimen by NAA with probe detection | |
| 100357-3 | | Naloxone [Presence] in Cord tissue by Screen method | |
| 100358-1 | | Phentermine [Presence] in Cord tissue by Screen method | |
| 100359-9 | | Gliadin 33 mer peptide [Mass/volume] in Stool by Immunoassay | |
| 10036-2 | | S wave amplitude in lead AVR | |
| 100360-7 | | Brief Resilience Scale panel [BRS] | |
| 100361-5 | | Quickly recover from bad events | |
| 100362-3 | | Difficulty making it through stressful events | |
| 100363-1 | | Easily recover from a stressful event | |
| 100364-9 | | Difficulty recovering from bad events | |
| 100365-6 | | Easily recover from difficulties | |
| 100366-4 | | Lengthy recovery from setbacks | |
| 100367-2 | | Total Score BRS | |
| 100368-0 | | Amino Acids Urea Cycle Panel - Serum or Plasma by LC/MS/MS | |
| 100369-8 | | NM Thyroid gland Views W Tl-201 IV | |
| 10037-0 | | S wave amplitude in lead I | |
| 100370-6 | | Orthopoxvirus DNA [Identifier] in Specimen by NAA with probe detection | |
| 100371-4 | | Titin Ab [Units/volume] in Serum by Immunoassay | |
| 100372-2 | | Abiraterone [Mass/volume] in Serum or Plasma | |
| 100373-0 | | Eucheuma IgG Ab [Units/volume] in Serum | |
| 100374-8 | | Aloe vera IgG Ab [Units/volume] in Serum | |
| 100375-5 | | Anise IgG Ab [Units/volume] in Serum | |
| 100376-3 | | Bambusa vulgaris IgG Ab [Units/volume] in Serum | |
| 100377-1 | | Goat cheese IgG Ab [Units/volume] in Serum | |
| 100378-9 | | Sheep cheese IgG Ab [Units/volume] in Serum | |
| 100379-7 | | Leeks IgG Ab [Units/volume] in Serum | |
| 10038-8 | | S wave amplitude in lead II | |
| 100380-5 | | Red cabbage IgG Ab [Units/volume] in Serum | |
| 100381-3 | | Mentha balsamea Wild IgG Ab [Units/volume] in Serum | |
| 100382-1 | | FDA package insert REMS addressed risk | |
| 100383-9 | | Monkeypox virus DNA [Presence] in Specimen by NAA with probe detection | |
| 100384-7 | | Rapeseed IgG Ab [Units/volume] in Serum | |
| 100385-4 | | Corn salad IgG Ab [Units/volume] in Serum | |
| 100386-2 | | Rosemary IgG Ab [Units/volume] in Serum | |
| 100387-0 | | Poppy Seed IgG Ab [Units/volume] in Serum | |
| 100388-8 | | Cocoa IgG Ab [Units/volume] in Serum | |
| 100389-6 | | Pistachio IgG Ab [Units/volume] in Serum | |
| 10039-6 | | S wave amplitude in lead III | |
| 100390-4 | | Sunflower Seed IgG Ab [Units/volume] in Serum | |
| 100391-2 | | Dates IgG Ab [Units/volume] in Serum | |
| 100392-0 | | Duck meat IgG Ab [Units/volume] in Serum | |
| 100393-8 | | Allergen Mushroom mix 2 (Xerocomus, Boletus) IgG Ab [Units/volume] in Serum | |
| 100394-6 | | Astacoidea IgG Ab [Units/volume] in Serum | |
| 100395-3 | | Carob IgG Ab [Units/volume] in Serum | |
| 100396-1 | | Brassica napus IgG Ab [Units/volume] in Serum | |
| 100397-9 | | Goat Meat IgG Ab [Units/volume] in Serum | |
| 100398-7 | | Goose meat IgG Ab [Units/volume] in Serum | |
| 100399-5 | | Ostrich meat IgG Ab [Units/volume] in Serum | |
| 1004-1 | | Direct antiglobulin test.complement specific reagent [Presence] on Red Blood Cells | |
| 10040-4 | | S wave amplitude in lead V1 | |
| 100400-1 | | Quail meat IgG Ab [Units/volume] in Serum | |
| 100401-9 | | Rabbit meat IgG Ab [Units/volume] in Serum | |
| 100402-7 | | Venison meat IgG Ab [Units/volume] in Serum | |
| 100403-5 | | Guineafowl IgG Ab [Units/volume] in Serum | |
| 100404-3 | | Horse meat IgG Ab [Units/volume] in Serum | |
| 100405-0 | | Kefir IgG Ab [Units/volume] in Serum | |
| 100406-8 | | Butter IgG Ab [Units/volume] in Serum | |
| 100407-6 | | Camembert cheese IgG Ab [Units/volume] in Serum | |
| 100408-4 | | Emmental cheese IgG Ab [Units/volume] in Serum | |
| 100409-2 | | Processed cheese IgG Ab [Units/volume] in Serum | |
| 10041-2 | | S wave amplitude in lead V2 | |
| 100410-0 | | Curd cheese IgG Ab [Units/volume] in Serum | |
| 100411-8 | | Sugar Beet IgG Ab [Units/volume] in Serum | |
| 100412-6 | | Chinese cabbage IgG Ab [Units/volume] in Serum | |
| 100413-4 | | Fennel Fresh IgG Ab [Units/volume] in Serum | |
| 100414-2 | | Gourd IgG Ab [Units/volume] in Serum | |
| 100415-9 | | Kale IgG Ab [Units/volume] in Serum | |
| 100416-7 | | Savoy cabbage IgG Ab [Units/volume] in Serum | |
| 100417-5 | | Vitis sp leaf IgG Ab [Units/volume] in Serum | |
| 100418-3 | | Liquorice IgG Ab [Units/volume] in Serum | |
| 100419-1 | | Snow pea IgG Ab [Units/volume] in Serum | |
| 10042-0 | | S wave amplitude in lead V3 | |
| 100420-9 | | Fava bean IgG Ab [Units/volume] in Serum | |
| 100421-7 | | Chick Pea IgG Ab [Units/volume] in Serum | |
| 100422-5 | | Chicory IgG Ab [Units/volume] in Serum | |
| 100423-3 | | Allergy Mushroom Mix 1 (Button + oyster + Shiitaki + chanterelle mushroom) IgG Ab [Units/volume] in Serum | |
| 100424-1 | | 8(9)-Cholestenol [Mass/volume] in Serum or Plasma | |
| 100425-8 | | DiHydro T-Mas [Mass/volume] in Serum or Plasma | |
| 100426-6 | | Squalene [Mass/volume] in Serum or Plasma | |
| 100427-4 | | Stigmasterol [Mass/volume] in Serum or Plasma | |
| 100428-2 | | Carnitine free and total and acylcarnitine panel - Urine | |
| 100429-0 | | LRBA deficiency panel - Blood | |
| 10043-8 | | S wave amplitude in lead V4 | |
| 100430-8 | | Cells.LRBA+/100 Cells.CD3+CD14-CD45+ in Blood by Flow cytometry (FC) | |
| 100431-6 | | Cells.CD3+CD14-CD45+.LRBA mean fluorescence intensity in Blood by Flow cytometry (FC) | |
| 100432-4 | | Cells.LRBA+/100 Cells.CD3-CD14-CD19+CD45+ in Blood by Flow cytometry (FC) | |
| 100433-2 | | Cells.CD3-CD14-CD19+CD45+.LRBA mean fluorescence intensity in Blood by Flow cytometry (FC) | |
| 100434-0 | | Orthopoxvirus.non-variola DNA [Presence] in Specimen by NAA with probe detection | |
| 100435-7 | | Glial fibrillary acidic protein [Mass/volume] in Serum by Immunoassay | |
| 100436-5 | | Ubiquitin carboxyl-terminal hydrolase-L1 [Mass/volume] in Serum by Immunoassay | |
| 100437-3 | | Norsufentanil [Mass/volume] in Urine by Confirmatory method | |
| 100438-1 | | Adolescent medicine Outpatient Progress note | |
| 100439-9 | | Allergy and Immunology Outpatient Progress note | |
| 10044-6 | | S wave amplitude in lead V5 | |
| 100440-7 | | Allergy Outpatient Progress note | |
| 100441-5 | | Attending Outpatient Progress note | |
| 100442-3 | | Audiology Outpatient Progress note | |
| 100443-1 | | Bariatric surgery Outpatient Progress note | |
| 100444-9 | | Blood banking and transfusion medicine Outpatient Progress note | |
| 100445-6 | | Bone Marrow Transplant Outpatient Progress note | |
| 100446-4 | | Breastfeeding Outpatient Progress note | |
| 100447-2 | | Burn management Outpatient Progress note | |
| 100448-0 | | Cardiac surgery Outpatient Progress note | |
| 100449-8 | | Cardiopulmonary Outpatient Progress note | |
| 10045-3 | | S wave amplitude in lead V6 | |
| 100450-6 | | Child and adolescent psychiatry Outpatient Progress note | |
| 100451-4 | | Chiropractic medicine Outpatient Progress note | |
| 100452-2 | | Clinical cardiac electrophysiology Outpatient Progress note | |
| 100453-0 | | Clinical genetics Outpatient Progress note | |
| 100454-8 | | Clinical neurophysiology Outpatient Progress note | |
| 100455-5 | | Clinical pathology Outpatient Progress note | |
| 100456-3 | | Colon and rectal surgery Outpatient Progress note | |
| 100457-1 | | Consultant Outpatient Progress note | |
| 100458-9 | | Outpatient COVID-19 Intubation Progress note | |
| 100459-7 | | Outpatient COVID-19 Progress note | |
| 10046-1 | | S wave duration in lead AVF | |
| 100460-5 | | Dermatology Outpatient Progress note | |
| 100461-3 | | Developmental-behavioral pediatrics Outpatient Progress note | |
| 100462-1 | | Dialysis and Therapeutic apheresis Outpatient Progress note | |
| 100463-9 | | Eating disorders Outpatient Progress note | |
| 100464-7 | | Endocrinology Outpatient Progress note | |
| 100465-4 | | Family medicine Outpatient Progress note | |
| 100466-2 | | Gastroenterology Outpatient Progress note | |
| 100467-0 | | Geriatric medicine Outpatient Progress note | |
| 100468-8 | | Gynecologic oncology Outpatient Progress note | |
| 100469-6 | | Gynecology Outpatient Progress note | |
| 10047-9 | | S wave duration in lead AVL | |
| 100470-4 | | Healthcare navigator Outpatient Progress note | |
| 100471-2 | | Heart failure Outpatient Progress note | |
| 100472-0 | | Heart failure+Transplant cardiology Outpatient Progress note | |
| 100473-8 | | Hematology Outpatient Progress note | |
| 100474-6 | | Hematology+Medical oncology Outpatient Progress note | |
| 100475-3 | | Hepatology Outpatient Progress note | |
| 100476-1 | | Immunology Outpatient Progress note | |
| 100477-9 | | Infectious disease Outpatient Progress note | |
| 100478-7 | | Internal medicine Outpatient Progress note | |
| 100479-5 | | Interventional cardiology Outpatient Progress note | |
| 10048-7 | | S wave duration in lead AVR | |
| 100480-3 | | Interventional radiology Outpatient Progress note | |
| 100481-1 | | Outpatient Mechanical circulatory support Progress note | |
| 100482-9 | | Medical Aid in Dying Outpatient Progress note | |
| 100483-7 | | Mental health Outpatient Progress note | |
| 100484-5 | | Multi-specialty program Outpatient Progress note | |
| 100485-2 | | Neonatal perinatal medicine Outpatient Progress note | |
| 100486-0 | | Nephrology Outpatient Progress note | |
| 100487-8 | | Neurological surgery Outpatient Progress note | |
| 100488-6 | | Neurology Outpatient Progress note | |
| 100489-4 | | Neurology with special qualifications in child neurology Outpatient Progress note | |
| 10049-5 | | S wave duration in lead I | |
| 100490-2 | | Nurse practitioner Outpatient Progress note | |
| 100491-0 | | Nurse Outpatient Progress note | |
| 100492-8 | | Nutrition and dietetics Outpatient Progress note | |
| 100493-6 | | Obstetrics and Gynecology Outpatient Progress note | |
| 100494-4 | | Obstetrics Outpatient Progress note | |
| 100495-1 | | Occupational therapy Outpatient Progress note | |
| 100496-9 | | Oncology Outpatient Progress note | |
| 100497-7 | | Ophthalmology Outpatient Progress note | |
| 100498-5 | | Optometry Outpatient Progress note | |
| 100499-3 | | Oral and Maxillofacial Surgery Outpatient Progress note | |
| 1005-8 | | Indirect antiglobulin test.IgG specific reagent [Presence] in Serum or Plasma | |
| 10050-3 | | S wave duration in lead II | |
| 100500-8 | | Orthopaedic surgery Outpatient Progress note | |
| 100501-6 | | Orthotics prosthetics Outpatient Progress note | |
| 100502-4 | | Otolaryngology Outpatient Progress note | |
| 100503-2 | | Pain medicine Outpatient Progress note | |
| 100504-0 | | Palliative care Outpatient Progress note | |
| 100505-7 | | Pediatric cardiology Outpatient Progress note | |
| 100506-5 | | Pediatric dermatology Outpatient Progress note | |
| 100507-3 | | Pediatric endocrinology Outpatient Progress note | |
| 100508-1 | | Pediatric gastroenterology Outpatient Progress note | |
| 100509-9 | | Pediatric hematology-oncology Outpatient Progress note | |
| 10051-1 | | S wave duration in lead III | |
| 100510-7 | | Pediatric infectious diseases Outpatient Progress note | |
| 100511-5 | | Pediatric otolaryngology Outpatient Progress note | |
| 100512-3 | | Pediatric pulmonology Outpatient Progress note | |
| 100513-1 | | Pediatric rheumatology Outpatient Progress note | |
| 100514-9 | | Pediatric surgery Outpatient Progress note | |
| 100515-6 | | Pediatric transplant hepatology Outpatient Progress note | |
| 100516-4 | | Pediatric urology Outpatient Progress note | |
| 100517-2 | | Pharmacogenomics Outpatient Progress note | |
| 100518-0 | | Physical medicine and rehab Outpatient Progress note | |
| 100519-8 | | Physical therapy Outpatient Progress note | |
| 10052-9 | | S wave duration in lead V1 | |
| 100520-6 | | Plastic surgery Outpatient Progress note | |
| 100521-4 | | Podiatry Outpatient Progress note | |
| 100522-2 | | Psychiatry Hospital Progress note | |
| 100523-0 | | Psychology Outpatient Progress note | |
| 100524-8 | | Pulmonary Outpatient Progress note | |
| 100525-5 | | Radiation oncology Outpatient Progress note | |
| 100526-3 | | Radiology Outpatient Progress note | |
| 100527-1 | | Recreational therapy Outpatient Progress note | |
| 100528-9 | | Reproductive endocrinology and infertility Outpatient Progress note | |
| 100529-7 | | Research Outpatient Progress note | |
| 10053-7 | | S wave duration in lead V2 | |
| 100530-5 | | Rheumatology Outpatient Progress note | |
| 100531-3 | | Sleep medicine Outpatient Progress note | |
| 100532-1 | | Social worker Outpatient Progress note | |
| 100533-9 | | Solid Organ Transplant Outpatient Progress note | |
| 100534-7 | | Speech-language pathology Outpatient Progress note | |
| 100535-4 | | Spinal surgery Outpatient Progress note | |
| 100536-2 | | Sports medicine Outpatient Progress note | |
| 100537-0 | | Surgery of the hand Outpatient Progress note | |
| 100538-8 | | Telehealth+Outpatient Progress note | |
| 100539-6 | | Thromboembolism Outpatient Progress note | |
| 10054-5 | | S wave duration in lead V3 | |
| 100540-4 | | Transplant surgery Outpatient Progress note | |
| 100541-2 | | Trauma Outpatient Progress note | |
| 100542-0 | | Urology Outpatient Progress note | |
| 100543-8 | | Vascular neurology Outpatient Progress note | |
| 100544-6 | | Vascular surgery Outpatient Progress note | |
| 100545-3 | | Wound care management Outpatient Progress note | |
| 100546-1 | | Wound, Ostomy, and Continence Care Outpatient Progress note | |
| 100547-9 | | Adolescent medicine Hospital Progress note | |
| 100548-7 | | Allergy and Immunology Hospital Progress note | |
| 100549-5 | | Allergy Hospital Progress note | |
| 10055-2 | | S wave duration in lead V4 | |
| 100550-3 | | Attending Hospital Progress note | |
| 100551-1 | | Audiology Hospital Progress note | |
| 100552-9 | | Bariatric surgery Hospital Progress note | |
| 100553-7 | | Blood banking and transfusion medicine Hospital Progress note | |
| 100554-5 | | Bone Marrow Transplant Hospital Progress note | |
| 100555-2 | | Breastfeeding Hospital Progress note | |
| 100556-0 | | Burn management Hospital Progress note | |
| 100557-8 | | Cardiac surgery Hospital Progress note | |
| 100558-6 | | Cardiopulmonary Hospital Progress note | |
| 100559-4 | | Child and adolescent psychiatry Hospital Progress note | |
| 10056-0 | | S wave duration in lead V5 | |
| 100560-2 | | Clinical cardiac electrophysiology Hospital Progress note | |
| 100561-0 | | Clinical genetics Hospital Progress note | |
| 100562-8 | | Clinical neurophysiology Hospital Progress note | |
| 100563-6 | | Clinical pathology Hospital Progress note | |
| 100564-4 | | Colon and rectal surgery Hospital Progress note | |
| 100565-1 | | Consultant Hospital Progress note | |
| 100566-9 | | Dentistry Hospital Progress note | |
| 100567-7 | | Dermatology Hospital Progress note | |
| 100568-5 | | Developmental-behavioral pediatrics Hospital Progress note | |
| 100569-3 | | Dialysis and Therapeutic apheresis Hospital Progress note | |
| 10057-8 | | S wave duration in lead V6 | |
| 100570-1 | | Eating disorders Hospital Progress note | |
| 100571-9 | | Endocrinology Hospital Progress note | |
| 100572-7 | | Family medicine Hospital Progress note | |
| 100573-5 | | Gastroenterology Hospital Progress note | |
| 100574-3 | | General medicine Hospital Progress note | |
| 100575-0 | | Geriatric medicine Hospital Progress note | |
| 100576-8 | | Gynecologic oncology Hospital Progress note | |
| 100577-6 | | Gynecology Hospital Progress note | |
| 100578-4 | | Healthcare navigator Hospital Progress note | |
| 100579-2 | | Heart failure Hospital Progress note | |
| 10058-6 | | S' wave amplitude in lead AVF | |
| 100580-0 | | Heart failure+Transplant cardiology Hospital Progress note | |
| 100581-8 | | Hematology Hospital Progress note | |
| 100582-6 | | Hematology+Medical oncology Hospital Progress note | |
| 100583-4 | | Hepatology Hospital Progress note | |
| 100584-2 | | Immunology Hospital Progress note | |
| 100585-9 | | Infectious disease Hospital Progress note | |
| 100586-7 | | Internal medicine Hospital Progress note | |
| 100587-5 | | Interventional cardiology Hospital Progress note | |
| 100588-3 | | Interventional radiology Hospital Progress note | |
| 100589-1 | | Hospital Mechanical circulatory support Progress note | |
| 10059-4 | | S' wave amplitude in lead AVL | |
| 100590-9 | | Medical Aid in Dying Hospital Progress note | |
| 100591-7 | | Mental health Hospital Progress note | |
| 100592-5 | | Multi-specialty program Hospital Progress note | |
| 100593-3 | | Neonatal perinatal medicine Hospital Progress note | |
| 100594-1 | | Nephrology Hospital Progress note | |
| 100595-8 | | Neurological surgery Hospital Progress note | |
| 100596-6 | | Neurology Hospital Progress note | |
| 100597-4 | | Neurology with special qualifications in child neurology Hospital Progress note | |
| 100598-2 | | Nurse practitioner Hospital Progress note | |
| 100599-0 | | Nurse Hospital Progress note | |
| 1006-6 | | Direct antiglobulin test.IgG specific reagent [Interpretation] on Red Blood Cells | |
| 10060-2 | | S' wave amplitude in lead AVR | |
| 100600-6 | | Nutrition and dietetics Hospital Progress note | |
| 100601-4 | | Obstetrics and Gynecology Hospital Progress note | |
| 100602-2 | | Obstetrics Hospital Progress note | |
| 100603-0 | | Occupational therapy Hospital Progress note | |
| 100604-8 | | Oncology Hospital Progress note | |
| 100605-5 | | Ophthalmology Hospital Progress note | |
| 100606-3 | | Oral and Maxillofacial Surgery Hospital Progress note | |
| 100607-1 | | Orthopaedic surgery Hospital Progress note | |
| 100608-9 | | Orthotics prosthetics Hospital Progress note | |
| 100609-7 | | Otolaryngology Hospital Progress note | |
| 10061-0 | | S' wave amplitude in lead I | |
| 100610-5 | | Pain medicine Hospital Progress note | |
| 100611-3 | | Palliative care Hospital Progress note | |
| 100612-1 | | Pastoral care Hospital Progress note | |
| 100613-9 | | Pediatric cardiology Hospital Progress note | |
| 100614-7 | | Pediatric dermatology Hospital Progress note | |
| 100615-4 | | Pediatric endocrinology Hospital Progress note | |
| 100616-2 | | Pediatric gastroenterology Hospital Progress note | |
| 100617-0 | | Pediatric hematology-oncology Hospital Progress note | |
| 100618-8 | | Pediatric infectious diseases Hospital Progress note | |
| 100619-6 | | Pediatric otolaryngology Hospital Progress note | |
| 10062-8 | | S' wave amplitude in lead II | |
| 100620-4 | | Pediatric pulmonology Hospital Progress note | |
| 100621-2 | | Pediatric rheumatology Hospital Progress note | |
| 100622-0 | | Pediatric surgery Hospital Progress note | |
| 100623-8 | | Pediatric transplant hepatology Hospital Progress note | |
| 100624-6 | | Pharmacogenomics Hospital Progress note | |
| 100625-3 | | Pharmacology Hospital Progress note | |
| 100626-1 | | Physical medicine and rehab Hospital Progress note | |
| 100627-9 | | Physical therapy Hospital Progress note | |
| 100628-7 | | Plastic surgery Hospital Progress note | |
| 100629-5 | | Podiatry Hospital Progress note | |
| 10063-6 | | S' wave amplitude in lead III | |
| 100630-3 | | Psychology Hospital Progress note | |
| 100631-1 | | Radiation oncology Hospital Progress note | |
| 100632-9 | | Radiology Hospital Progress note | |
| 100633-7 | | Rapid response team Hospital Progress note | |
| 100634-5 | | Recreational therapy Hospital Progress note | |
| 100635-2 | | Reproductive endocrinology and infertility Hospital Progress note | |
| 100636-0 | | Research Hospital Progress note | |
| 100637-8 | | Rheumatology Hospital Progress note | |
| 100638-6 | | Sleep medicine Hospital Progress note | |
| 100639-4 | | Social worker Hospital Progress note | |
| 10064-4 | | S' wave amplitude in lead V1 | |
| 100640-2 | | Solid Organ Transplant Hospital Progress note | |
| 100641-0 | | Speech-language pathology Hospital Progress note | |
| 100642-8 | | Spinal surgery Hospital Progress note | |
| 100643-6 | | Surgery of the hand Hospital Progress note | |
| 100644-4 | | Thromboembolism Hospital Progress note | |
| 100645-1 | | Trauma Hospital Progress note | |
| 100646-9 | | Urology Hospital Progress note | |
| 100647-7 | | Vascular neurology Hospital Progress note | |
| 100648-5 | | Vascular surgery Hospital Progress note | |
| 100649-3 | | Wound care management Hospital Progress note | |
| 10065-1 | | S' wave amplitude in lead V2 | |
| 100650-1 | | Wound, Ostomy, and Continence Care Hospital Progress note | |
| 100651-9 | | Hospital COVID-19 Intubation Progress note | |
| 100652-7 | | Pure tone bone conduction threshold audiometry panel | |
| 100653-5 | | Pure tone air conduction threshold audiometry panel | |
| 100654-3 | | Pyruvate kinase M2 [Presence] in Stool | |
| 100655-0 | | XR Sella turcica Lateral | |
| 100656-8 | | Maternal and fetal medicine Outpatient Progress note | |
| 100657-6 | | Maternal and fetal medicine Telephone encounter+Hospital Progress note | |
| 100658-4 | | Hospital COVID-19 Progress note | |
| 100659-2 | | Maternal and fetal medicine Hospital Progress note | |
| 10066-9 | | S' wave amplitude in lead V3 | |
| 100660-0 | | Maternal and fetal medicine Telephone encounter+Outpatient Progress note | |
| 100661-8 | | Psychiatry Outpatient Progress note | |
| 100662-6 | | Cortisol free and total panel - Serum or Plasma | |
| 100663-4 | | TPMT gene c.460G>A and c.719A>G [Presence] in Blood by Molecular genetics method | |
| 100664-2 | | NUDT15 gene c.50_55dup and c.415C>T [Presence] in Blood by Molecular genetics method | |
| 100665-9 | | NUDT15 gene c.415C>T [Presence] in Blood by Molecular genetics method | |
| 100666-7 | | NUDT15 gene c.416G>A [Presence] in Blood by Molecular genetics method | |
| 100667-5 | | NUDT15 gene c.52G>A [Presence] in Blood by Molecular genetics method | |
| 100668-3 | | NUDT15 gene c.50_55dup [Presence] in Blood by Molecular genetics method | |
| 100669-1 | | NUDT15 gene c.50_55del [Presence] in Blood by Molecular genetics method | |
| 10067-7 | | S' wave amplitude in lead V4 | |
| 100670-9 | | RHD gene allele [Identifier] in Plasma cell-free DNA Nominal--fetus | |
| 100671-7 | | Aspergillus sp DNA [Presence] in Blood by NAA with probe detection | |
| 100672-5 | | Aspergillus fumigatus DNA [Presence] in Blood by NAA with probe detection | |
| 100673-3 | | Aspergillus terreus DNA [Presence] in Blood by NAA with probe detection | |
| 100674-1 | | BK virus DNA [Log #/volume] (viral load) in Blood by NAA with probe detection | |
| 100675-8 | | Cytomegalovirus DNA [Units/volume] (viral load) in Blood by NAA with probe detection | |
| 100676-6 | | Cytomegalovirus DNA [log units/volume] (viral load) in Blood by NAA with probe detection | |
| 100677-4 | | Epstein Barr virus DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection | |
| 100678-2 | | Epstein Barr virus DNA [Log #/volume] (viral load) in Blood by NAA with probe detection | |
| 100679-0 | | Herpes virus 6 DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection | |
| 10068-5 | | S' wave amplitude in lead V5 | |
| 100680-8 | | Herpes virus 6 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection | |
| 100681-6 | | Herpes virus 7 DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection | |
| 100682-4 | | Herpes virus 7 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection | |
| 100683-2 | | Herpes virus 8 DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection | |
| 100684-0 | | Herpes virus 8 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection | |
| 100685-7 | | JC virus DNA [Log #/volume] (viral load) in Serum or Plasma by NAA with probe detection | |
| 100686-5 | | JC virus DNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection | |
| 100687-3 | | JC virus DNA [Log #/volume] (viral load) in Urine by NAA with probe detection | |
| 100688-1 | | Parvovirus B19 DNA [Log #/volume] (viral load) in Blood by NAA with probe detection | |
| 100689-9 | | Toxoplasma gondii DNA [Log #/volume] in Serum or Plasma by NAA with probe detection | |
| 10069-3 | | S' wave amplitude in lead V6 | |
| 100690-7 | | Toxoplasma gondii DNA [Log #/volume] in Cerebral spinal fluid by NAA with probe detection | |
| 100691-5 | | Varicella zoster virus DNA [Log #/volume] (viral load) in Blood by NAA with probe detection | |
| 100692-3 | | Varicella zoster virus DNA [Log #/volume] (viral load) in Cerebral spinal fluid by NAA with probe detection | |
| 100693-1 | | Pneumocystis jiroveci DNA [Log #/volume] in Respiratory specimen by NAA with probe detection | |
| 100694-9 | | SMN1 gene silent carrier analysis [Presence] in Blood or Tissue by Molecular genetics method | |
| 100695-6 | | Genetic disease analysis overall carrier interpretation in Blood or Tissue by Molecular genetics method Narrative | |
| 100696-4 | | CTNS related multigene analysis [Identifier] in Bodyfluid and Serum or Plasma by Molecular genetics method Nominal | |
| 100697-2 | | Interventional radiology Outpatient Note | |
| 100698-0 | | Social Determinants of Health screening report Document | |
| 100699-8 | | Rifabutin+Ethambutol [Susceptibility] | |
| 1007-4 | | Direct antiglobulin test.polyspecific reagent [Presence] on Red Blood Cells | |
| 10070-1 | | S' wave duration in lead AVF | |
| 100700-4 | | Trichomonas vaginalis DNA [Presence] in Urethra by NAA with probe detection | |
| 100701-2 | | Trichomonas vaginalis rRNA [Presence] in Urethra by NAA with probe detection | |
| 100702-0 | | Mycoplasma genitalium rRNA [Presence] in Urethra by NAA with probe detection | |
| 100703-8 | | Mycoplasma genitalium rRNA [Presence] in Urine by NAA with probe detection | |
| 100704-6 | | Mycoplasma genitalium rRNA [Presence] in Cervix by NAA with probe detection | |
| 100705-3 | | Mycoplasma genitalium rRNA [Presence] in Anorectal by NAA with probe detection | |
| 100706-1 | | Mycoplasma genitalium rRNA [Presence] in Specimen by NAA with probe detection | |
| 100707-9 | | Polymorphonuclear cells [#/volume] in Peritoneal dialysis fluid by Automated count | |
| 100708-7 | | Plasma cells/100 leukocytes in Synovial fluid | |
| 100709-5 | | Hepatocellular carcinoma risk [Score] by GAAD | |
| 10071-9 | | S' wave duration in lead AVL | |
| 100710-3 | | Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Throat by NAA with probe detection | |
| 100711-1 | | Borrelia burgdorferi.VlsE1+pepC10 Ab [Units/volume] in Serum by Immunoassay | |
| 100712-9 | | Brexpiprazole [Mass/volume] in Serum or Plasma | |
| 100713-7 | | Cariprazine [Mass/volume] in Serum or Plasma | |
| 100714-5 | | Guanfacine [Mass/volume] in Serum or Plasma | |
| 100715-2 | | Prothipendyl [Mass/volume] in Serum or Plasma | |
| 100716-0 | | Prostate specific Ag [Mass/volume] in DBS | |
| 100717-8 | | FCGR3A gene.p.Phe176Val [Presence] in Blood or Tissue by Molecular genetics method | |
| 100718-6 | | Undersea and hyperbaric medicine Discharge summary | |
| 100719-4 | | Surgical oncology Discharge summary | |
| 10072-7 | | S' wave duration in lead AVR | |
| 100720-2 | | Reproductive endocrinology and infertility Discharge summary | |
| 100721-0 | | Community health care Discharge summary | |
| 100722-8 | | Integrative medicine Discharge summary | |
| 100723-6 | | Sports medicine Discharge summary | |
| 100724-4 | | Diabetology Discharge summary | |
| 100725-1 | | Optometry Discharge summary | |
| 100726-9 | | Podiatry Discharge summary | |
| 100727-7 | | Chiropractic medicine Discharge summary | |
| 100728-5 | | Cardiac surgery Discharge summary | |
| 100729-3 | | Breastfeeding Discharge summary | |
| 10073-5 | | S' wave duration in lead I | |
| 100730-1 | | Transplant surgery Discharge summary | |
| 100731-9 | | Urgent care center Discharge summary | |
| 100732-7 | | Cholesterol.in lipoprotein (little a) and Cholesterol.in LDL panel - Serum | |
| 100733-5 | | Cholesterol in LDL [Mass/volume] in Serum by calculation --corrected for Cholesterol.in lipoprotein (little a) | |
| 100734-3 | | traMADol and Metabolites Panel - Urine by Confirmatory method | |
| 100735-0 | | Mannose-6-phosphate isomerase and phosphomannomutase 1 panel - Leukocytes | |
| 100736-8 | | Acylcarnitine Analysis Post Mortem in Specimen Document | |
| 100737-6 | | Alkaline phosphatase.macromolecular [Presence] in Serum or Plasma | |
| 100738-4 | | Alanine aminotransferase.macromolecular [Presence] in Serum or Plasma | |
| 100739-2 | | Aspartate aminotransferase.macromolecular [Presence] in Serum or Plasma | |
| 10074-3 | | S' wave duration in lead II | |
| 100740-0 | | Amylase.macromolecular [Presence] in Serum or Plasma | |
| 100741-8 | | Gamma glutamyl transferase.macromolecular [Presence] in Serum or Plasma | |
| 100742-6 | | Lactate dehydrogenase.macromolecular [Presence] in Serum or Plasma | |
| 100743-4 | | Lipase.macromolecular [Presence] in Serum or Plasma | |
| 100744-2 | | Alpha-1-acid glycoprotein [Mass/volume] in Serum or Plasma by Electrophoresis | |
| 100745-9 | | Chloride [Moles/volume] in Mixed venous blood | |
| 100746-7 | | Glucose [Moles/volume] in Mixed venous blood | |
| 100747-5 | | Legionella serogroup panel - Specimen | |
| 100748-3 | | Legionella spp [Presence] in Specimen by NAA with probe detection | |
| 100749-1 | | Legionella pneumophila serogroup 1 [Presence] in Specimen by NAA with probe detection | |
| 10075-0 | | S' wave duration in lead III | |
| 100750-9 | | Legionella pneumophila non-serogroup 1 [Presence] in Specimen by NAA with probe detection | |
| 100751-7 | | Galactose-alpha-1,3-galactose (Alpha-Gal) panel - Serum or Plasma | |
| 100752-5 | | Exacerbating factors - Reported | |
| 100753-3 | | Alleviating factors - Reported | |
| 100754-1 | | Platelet disorders multigene analysis in Blood or Tissue by Sequencing | |
| 100755-8 | | Oligoclonal bands [#] in Serum or Plasma by Isoelectric focusing | |
| 100756-6 | | Oligoclonal bands [Interpretation] in Cerebral spinal fluid by Isoelectric focusing | |
| 100757-4 | | Protein fractions.oligoclonal bands panel - Serum and CSF by Isoelectric focusing | |
| 100758-2 | | Estimated lung age by based on clinical data | |
| 100759-0 | | Inspiratory reserve [Volume] Respiratory system by Spirometry | |
| 10076-8 | | S' wave duration in lead V1 | |
| 100760-8 | | XR Radius and Ulna - left Single view | |
| 100761-6 | | PALB2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method | |
| 100762-4 | | HBA2 gene.c.377T>C [Presence] in Blood by Molecular genetics method | |
| 100763-2 | | Mycobacterium sp comparative reaction interpretation Narrative | |
| 100764-0 | | Mycobacterium bovis reaction wheal [Diameter] Qualitative --3 days post dose mammalian tuberculin intradermal | |
| 100765-7 | | Homocysteine and methylmalonate and methylcitrate panel - DBS | |
| 100766-5 | | Center for Epidemiologic Studies Depression Scale panel [CES-D] | |
| 100767-3 | | Bothered by things that are not usually bothersome | |
| 100768-1 | | Poor appetite | |
| 100769-9 | | Unhappy even with help from my family or friends | |
| 10077-6 | | S' wave duration in lead V2 | |
| 100770-7 | | Feeling just as good as others | |
| 100771-5 | | Trouble focusing | |
| 100772-3 | | Feeling depressed | |
| 100773-1 | | Feeling everything is too much of an effort | |
| 100774-9 | | Feeling hopeful about the future | |
| 100775-6 | | Feeling life had been a failure | |
| 100776-4 | | Feeling fearful | |
| 100777-2 | | Restless sleep | |
| 100778-0 | | Feeling happy | |
| 100779-8 | | Quieter than usual | |
| 10078-4 | | S' wave duration in lead V3 | |
| 100780-6 | | Feeling lonely | |
| 100781-4 | | People were unfriendly | |
| 100782-2 | | Enjoying life | |
| 100783-0 | | Crying spells | |
| 100784-8 | | Feeling sad | |
| 100785-5 | | Feeling people dislike me | |
| 100786-3 | | Lack of energy | |
| 100787-1 | | Total Score CES-D | |
| 100788-9 | | Stemphylium botryosum IgG4 Ab [Mass/volume] in Serum | |
| 100789-7 | | Rhizopus nigricans IgG4 Ab [Mass/volume] in Serum | |
| 10079-2 | | S' wave duration in lead V4 | |
| 100790-5 | | Lepidoglyphus destructor IgG Ab [Mass/volume] in Serum | |
| 100791-3 | | Hamster epithelium IgG Ab [Mass/volume] in Serum | |
| 100792-1 | | Forsythia IgE Ab [Units/volume] in Serum | |
| 100793-9 | | Testosterone [Mass/volume] in Body fluid | |
| 100794-7 | | Follitropin [Units/volume] in Body fluid | |
| 100795-4 | | S100 calcium binding protein B [Mass/volume] in Body fluid | |
| 100796-2 | | Thyroglobulin [Mass/volume] in Body fluid | |
| 100797-0 | | Testosterone Free [Mass/volume] in Serum --1st specimen post XXX challenge | |
| 100798-8 | | Testosterone Free [Mass/volume] in Serum --2nd specimen post XXX challenge | |
| 100799-6 | | 21-Deoxycortisol [Mass/volume] in Serum --1st specimen post XXX challenge | |
| 1008-2 | | Indirect antiglobulin test.polyspecific reagent [Presence] in Serum or Plasma | |
| 10080-0 | | S' wave duration in lead V5 | |
| 100800-2 | | 21-Deoxycortisol [Mass/volume] in Serum --2nd specimen post XXX challenge | |
| 100801-0 | | 21-Deoxycortisol [Mass/volume] in Serum --3rd specimen post XXX challenge | |
| 100802-8 | | 21-Deoxycortisol [Mass/volume] in Serum --4th specimen post XXX challenge | |
| 100803-6 | | 21-Deoxycortisol [Mass/volume] in Serum --5th specimen post XXX challenge | |
| 100804-4 | | Vasopressin [Moles/volume] in Plasma --1st specimen post XXX challenge | |
| 100805-1 | | Vasopressin [Moles/volume] in Plasma --2nd specimen post XXX challenge | |
| 100806-9 | | Vasopressin [Moles/volume] in Plasma --3rd specimen post XXX challenge | |
| 100807-7 | | Vasopressin [Moles/volume] in Plasma --4th specimen post XXX challenge | |
| 100808-5 | | Vasopressin [Moles/volume] in Plasma --5th specimen post XXX challenge | |
| 100809-3 | | Vasopressin [Moles/volume] in Plasma --6th specimen post XXX challenge | |
| 10081-8 | | S' wave duration in lead V6 | |
| 100810-1 | | Vasopressin [Moles/volume] in Plasma --7th specimen post XXX challenge | |
| 100811-9 | | Vasopressin [Moles/volume] in Plasma --8th specimen post XXX challenge | |
| 100812-7 | | Vasopressin [Moles/volume] in Plasma --9th specimen post XXX challenge | |
| 100813-5 | | Vasopressin [Moles/volume] in Plasma --10th specimen post XXX challenge | |
| 100814-3 | | Vasopressin [Moles/volume] in Plasma --11th specimen post XXX challenge | |
| 100815-0 | | Vasopressin [Moles/volume] in Plasma --12th specimen post XXX challenge | |
| 100816-8 | | Glucagon [Mass/volume] in Serum or Plasma --6th specimen post XXX challenge | |
| 100817-6 | | Glucagon [Mass/volume] in Serum or Plasma --7th specimen post XXX challenge | |
| 100818-4 | | Renin [Mass/volume] in Plasma --1st specimen post XXX challenge | |
| 100819-2 | | Renin [Mass/volume] in Plasma --2nd specimen post XXX challenge | |
| 10082-6 | | ST initial amplitude 6 ms in lead AVF | |
| 100820-0 | | Renin [Mass/volume] in Plasma --3rd specimen post XXX challenge | |
| 100821-8 | | National POLST form: portable medical order panel | |
| 100822-6 | | Cardiopulmonary resuscitation orders | |
| 100823-4 | | Initial portable medical treatment orders | |
| 100824-2 | | Additional portable medical orders or instructions | |
| 100825-9 | | Medically assisted nutrition orders | |
| 100826-7 | | Portable medical order AndOr advance directive review | |
| 100827-5 | | Portable medical order discussion participants | |
| 100828-3 | | Portable medical order administrative information | |
| 100829-1 | | Renin [Mass/volume] in Plasma --4th specimen post XXX challenge | |
| 10083-4 | | ST initial amplitude 6 ms in lead AVL | |
| 100830-9 | | Alpha subunit free [Units/volume] in Serum or Plasma --1st specimen post XXX challenge | |
| 100831-7 | | Alpha subunit free [Units/volume] in Serum or Plasma --2nd specimen post XXX challenge | |
| 100832-5 | | Alpha subunit free [Units/volume] in Serum or Plasma --3rd specimen post XXX challenge | |
| 100833-3 | | Alpha subunit free [Units/volume] in Serum or Plasma --4th specimen post XXX challenge | |
| 100834-1 | | Alpha subunit free [Units/volume] in Serum or Plasma --5th specimen post XXX challenge | |
| 100835-8 | | Alpha subunit free [Units/volume] in Serum or Plasma --6th specimen post XXX challenge | |
| 100836-6 | | Alpha subunit free [Units/volume] in Serum or Plasma --7th specimen post XXX challenge | |
| 100837-4 | | Insulin-like growth factor-I [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge | |
| 100838-2 | | Testosterone [Mass/volume] in Serum or Plasma --9th specimen post XXX challenge | |
| 100839-0 | | Vitamin A/Retinol binding protein [Ratio] in Serum or Plasma | |
| 10084-2 | | ST initial amplitude 6 ms in lead AVR | |
| 100840-8 | | IgE [Units/volume] in Body fluid | |
| 100841-6 | | Zinc finger protein of the cerebellum 4 Ab [Presence] in Cerebral spinal fluid by Line blot | |
| 100842-4 | | Nonalcoholic steatohepatitis score in Serum or Plasma Calculated by FAST | |
| 100843-2 | | Liver fibrosis score in Serum or Plasma by Calculated.Agile3+ | |
| 100844-0 | | Liver fibrosis score in Serum or Plasma by Calculated.Agile4 | |
| 100845-7 | | Neurofascin155 IgG4 Ab [Presence] in Serum by Flow cytometry (FC) | |
| 100846-5 | | Dengue virus 1+2+3+4 nsP1 IgG Ab [Presence] in Serum or Plasma by Immunoassay | |
| 100847-3 | | Gas and ammonia panel - Arterial blood | |
| 100848-1 | | Cell count and Differential panel - Amniotic fluid by Manual count | |
| 100849-9 | | Leukocytes [#/volume] in Amniotic fluid by Manual count | |
| 10085-9 | | ST initial amplitude 6 ms in lead I | |
| 100850-7 | | Neutrophils [#/volume] in Amniotic fluid by Manual count | |
| 100851-5 | | Other cells [#/volume] in Amniotic fluid by Manual count | |
| 100852-3 | | NM Bones Views for metastasis W Sr-89 IV | |
| 100853-1 | | NM Pericardial space Pericardial effusion | |
| 100854-9 | | Lymphocytes/100 cells in Blood mononuclear cells by Immunoassay | |
| 100855-6 | | CD3 cells/100 cells in Blood mononuclear cells | |
| 100856-4 | | CD3+CD4+ (T4 helper) cells/100 cells in Blood mononuclear cells | |
| 100857-2 | | CD3+CD8+ (T8 suppressor) cells/100 cells in Blood mononuclear cells | |
| 100858-0 | | Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide | |
| 100859-8 | | Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide | |
| 10086-7 | | ST initial amplitude 6 ms in lead II | |
| 100860-6 | | Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide | |
| 100861-4 | | Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide | |
| 100862-2 | | Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide | |
| 100863-0 | | Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide | |
| 100864-8 | | Giardia lamblia bg gene [Genotype] in Specimen by Molecular genetics method | |
| 100865-5 | | Avian schistosomes DNA [Presence] in Specimen by NAA with probe detection | |
| 100866-3 | | Febrile antibody profile in Serum | |
| 100867-1 | | Campylobacter jejuni+coli+lari+upsaliensis Ag [Presence] in Stool by Rapid immunoassay | |
| 100868-9 | | Cryptosporidium sp 18S-LC2 rRNA [Genotype] in Specimen by Molecular genetics method | |
| 100869-7 | | Cryptosporidium gp60 gene [Type] in Specimen by Molecular genetics method | |
| 10087-5 | | ST initial amplitude 6 ms in lead III | |
| 100870-5 | | Cryptosporidium 18S rRNA [Genotype] in Specimen by Molecular genetics method | |
| 100871-3 | | Giardia lamblia gdh gene [Genotype] in Specimen by Molecular genetics method | |
| 100872-1 | | Bacteria producing polysaccharide from sucrose [Presence] in Isolate | |
| 100873-9 | | Giardia lamblia tpi gene [Genotype] in Specimen by Molecular genetics method | |
| 100874-7 | | Basidiobolus sp [Presence] in Specimen | |
| 100875-4 | | Fetal Heart Document limited US | |
| 100876-2 | | Fetal Heart Document US | |
| 100877-0 | | US Heart Transesophageal during surgery | |
| 100878-8 | | Endoscopic ultrasound study Upper GI tract Document | |
| 100879-6 | | US Guidance for cryoablation of Breast - right | |
| 10088-3 | | ST initial amplitude 6 ms in lead V1 | |
| 100880-4 | | US Guidance for cryoablation of Breast - left | |
| 100881-2 | | MR Guidance for cryoablation of Bone | |
| 100882-0 | | MR Peritoneum W contrast percutaneous intraperitoneal | |
| 100883-8 | | MR Guidance for biopsy of Kidney - left | |
| 100884-6 | | MR Guidance for biopsy of Kidney - right | |
| 100885-3 | | Parapoxvirus DNA [Presence] in Specimen by NAA with probe detection | |
| 100886-1 | | Orf virus DNA [Presence] in Specimen by NAA with probe detection | |
| 100887-9 | | Pseudocowpox virus DNA [Presence] in Specimen by NAA with probe detection | |
| 100888-7 | | West African monkeypox virus DNA [Presence] in Specimen by NAA with probe detection | |
| 100889-5 | | Congo Basin monkeypox virus DNA [Presence] in Specimen by NAA with probe detection | |
| 10089-1 | | ST initial amplitude 6 ms in lead V2 | |
| 100890-3 | | Poxvirus DNA panel | |
| 100891-1 | | Orthopoxvirus IgG Ab [Presence] in Serum or Plasma by Immunoassay | |
| 100892-9 | | Orthopoxvirus IgM Ab [Presence] in Serum or Plasma by Immunoassay | |
| 100893-7 | | Orthopoxvirus IgG and IgM Ab panel - Serum or Plasma | |
| 100894-5 | | Recommended screening frequency Narrative | |
| 100895-2 | | Rickettsia conorii IgG and IgM [Interpretation] in Serum | |
| 100896-0 | | Vasopressin [Moles/volume] in Plasma --13th specimen post XXX challenge | |
| 100897-8 | | Staphylococcus aureus [Presence] in Specimen by Organism specific culture | |
| 100898-6 | | Lipid panel - Serum or Plasma | |
| 100899-4 | | Enterobacteriaceae.extended spectrum beta lactamase resistance phenotype [Identifier] in Specimen by Organism specific culture | |
jurisdiction[0]
Concept